Stroke thrombolysis: Save a minute, save a day

Stroke

Volumn 45, Issue 4, 2014, Pages 1053-1058

  Meretoja, Atte ^a,b,f   Keshtkaran, Mahsa ^b,e   Saver, Jeffrey L ^c   Tatlisumak, Turgut ^b   Parsons, Mark W ^d   Kaste, Markku ^a   Davis, Stephen M ^a   Donnan, Geoffrey A ^a   Churilov, Leonid ^a,e  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF NEWCASTLE   (Australia)

^e RMIT UNIVERSITY   (Australia)

^f ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; AUSTRALIA; BASILAR ARTERY OBSTRUCTION; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; COHORT ANALYSIS; DISABILITY; DISEASE SEVERITY; FEMALE; FIBRINOLYTIC THERAPY; FINLAND; HUMAN; LIFESPAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RANKIN SCALE; STROKE PATIENT; THERAPY DELAY; TIME TO TREATMENT; VERY ELDERLY;

STROKE; THROMBOLYTIC THERAPY;

AGED; AGED, 80 AND OVER; AUSTRALIA; DISABILITY EVALUATION; EMERGENCY MEDICAL SERVICES; FEMALE; FIBRINOLYTIC AGENTS; FINLAND; HUMANS; LIFE EXPECTANCY; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGISTRIES; STROKE; TIME-TO-TREATMENT;

EID: 84897396042     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.113.002910     Document Type: Article

References (31)

1. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, et al American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44:870-947.
2. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al; ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group. Time to treatment with intravenous alteplase and outcome in stroke: An updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375:1695-1703.
3. Saver JL. Time is brain-quantified. Stroke. 2006;37:263-266.
4. Meretoja A, Kaste M. Pre-And in-hospital intersection of stroke care. Ann N Y Acad Sci. 2012;1268:145-151.
5. Meretoja A, Strbian D, Mustanoja S, Tatlisumak T, Lindsberg PJ, Kaste M. Reducing in-hospital delay to 20 minutes in stroke thrombolysis. Neurology. 2012;79:306-313.
6. Fonarow GC, Smith EE, Saver JL, Reeves MJ, Bhatt DL, Grau-Sepulveda MV, et al. Timeliness of tissue-Type plasminogen activator therapy in acute ischemic stroke: Patient characteristics, hospital factors, and outcomes associated with door-To-needle times within 60 minutes. Circulation. 2011;123:750-758.
7. Simpson MA, Dewey HM, Churilov L, Ahmed N, Bladin CF, Schultz D, et al. Thrombolysis for acute stroke in Australia: Outcomes from the Safe Implementation of Thrombolysis in Stroke registry (2002-2008). Med J Aust. 2010;193:439-443.
8. Mikulík R, Kadlecová P, Czlonkowska A, Kobayashi A, Brozman M, Svigelj V, et al Safe Implementation of Treatments in Stroke-East Registry (SITS-EAST) Investigators. Factors influencing in-hospital delay in treatment with intravenous thrombolysis. Stroke. 2012;43:1578-1583.
9. Hong KS, Saver JL. Years of disability-Adjusted life gained as a result of thrombolytic therapy for acute ischemic stroke. Stroke. 2010;41:471-477.
10. Australian Bureau of Statistics. http://www.abs.gov.au/ausstats. Accessed March 15, 2013.
11. Wang H, Dwyer-Lindgren L, Lofgren KT, Rajaratnam JK, Marcus JR, Levin-Rector A, et al. Age-specific and sex-specific mortality in 187 countries, 1970-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2071-2094.
12. Hong KS, Saver JL. Quantifying the value of stroke disability outcomes: WHO global burden of disease project disability weights for each level of the modified Rankin Scale. Stroke. 2009;40:3828-3833.
13. Fox-Rushby JA, Hanson K. Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis. Health Policy Plan. 2001;16:326-331.
14. WHO. http://www.who.int/healthinfo/bod/en/index.html. Accessed March 15, 2013.
15. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-Adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2197-2223.
16. Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, et al SITS-MOST Investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): An observational study. Lancet. 2007;369:275-282.
17. Meretoja A, Putaala J, Tatlisumak T, Atula S, Artto V, Curtze S, et al. Off-label thrombolysis is not associated with poor outcome in patients with stroke. Stroke. 2010;41:1450-1458.
18. Strbian D, Soinne L, Sairanen T, Häppölä O, Lindsberg PJ, Tatlisumak T, et al Helsinki Stroke Thrombolysis Registry Group. Ultraearly thrombolysis in acute ischemic stroke is associated with better outcome and lower mortality. Stroke. 2010;41:712-716.
19. Saver JL, Fonarow GC, Smith EE, Reeves MJ, Grau-Sepulveda MV, Pan W, et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA. 2013;309:2480-2488.
20. Fonarow GC, Smith EE, Saver JL, Reeves MJ, Hernandez AF, Peterson ED, et al. Improving door-To-needle times in acute ischemic stroke: The design and rationale for the American Heart Association/American Stroke Association's Target: Stroke initiative. Stroke. 2011;42:2983-2989.
21. Köhrmann M, Schellinger PD, Breuer L, Dohrn M, Kuramatsu JB, Blinzler C, et al. Avoiding in hospital delays and eliminating the threehour effect in thrombolysis for stroke. Int J Stroke. 2011;6:493-497.
22. Ford AL, Williams JA, Spencer M, McCammon C, Khoury N, Sampson TR, et al. Reducing door-To-needle times using Toyota's lean manufacturing principles and value stream analysis. Stroke. 2012;43:3395-3398.
23. Tilley BC, Lyden PD, Brott TG, Lu M, Levine SR, Welch KM. Total quality improvement method for reduction of delays between emergency department admission and treatment of acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Arch Neurol. 1997;54:1466-1474.
24. Curtze S, Meretoja A, Mustanoja S, Putaala J, Lindberg T, Leppä M, et al. Does time of day or physician experience affect outcome of acute ischemic stroke patients treated with thrombolysis? A study from Finland. Int J Stroke. 2012;7:511-516.
25. Walter S, Kostopoulos P, Haass A, Keller I, Lesmeister M, Schlechtriemen T, et al. Diagnosis and treatment of patients with stroke in a mobile stroke unit versus in hospital: A randomised controlled trial. Lancet Neurol. 2012;11:397-404.
26. Weber JE, Ebinger M, Rozanski M, Waldschmidt C, Wendt M, Winter B, et al STEMO-Consortium. Prehospital thrombolysis in acute stroke: Results of the PHANTOM-S pilot study. Neurology. 2013;80:163-168.
27. Bluhmki E, Chamorro A, Dávalos A, Machnig T, Sauce C, Wahlgren N, et al. Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): Additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol. 2009;8:1095-1102.
28. Salomon JA, Vos T, Hogan DR, Gagnon M, Naghavi M, Mokdad A, et al. Common values in assessing health outcomes from disease and injury: Disability weights measurement study for the Global Burden of Disease Study 2010. Lancet. 2012;380:2129-2143.
29. Bembenek J, Kobayashi A, Sandercock P, Czlonkowska A. How many patients might receive thrombolytic therapy in the light of the ECASS-3 and IST-3 data? Int J Stroke. 2010;5:430-431.
30. de Los Rios la Rosa F, Khoury J, Kissela BM, Flaherty ML, Alwell K, Moomaw CJ, et al. Eligibility for intravenous recombinant tissue-Type plasminogen activator within a population: The Effect of the European Cooperative Acute Stroke Study (ECASS) III trial. Stroke. 2012;43:1591-1595.
31. Meretoja A, Weir L, Ugalde M, Yassi N, Yan B, Hand P, et al. Helsinki model cut stroke thrombolysis delays to 25 minutes in Melbourne in only 4 months. Neurology. 2013;81:1071-1076.